Pegvisomant bioavailability of single 30mg/mL subcutaneous injection compared to two 15mg/mL subcutaneous injections: A pharmacokinetic, safety and tolerability study

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The study was conducted to evaluate the pharmacokinetics (PK), relative bioavailability (relBA), safety and tolerability of two single-dose pegvisomant subcutaneous (SC) administrations: one injection of 30 mg/mL (1 × 30 mg/mL) versus two injections of two 15 mg/mL (2 × 15 mg/mL).

Related collections

Author and article information

Journal

Title: Growth Hormone & IGF Research

Abbreviated Title: Growth Hormone & IGF Research

Publisher: Elsevier BV

ISSN (Print): 10966374

Publication date Created: August 2013

Publication date (Print): August 2013

Volume: 23

Issue: 4

Pages: 114-119

Article

DOI: 10.1016/j.ghir.2013.04.002

PubMed ID: 23651793

SO-VID: 8e9c56db-7cd8-4128-a784-5434577c3794

History

Data availability:

Comments

Comment on this article

scite_